|Videos|April 4, 2018

Nurses & Disinfection Practices: What Role Do They Play?

Barley Chironda, RPN, CIC, explains the role that nurses play in disinfection practices at health care facilities.

Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, explains the role that nurses play in disinfection practices at health care facilities.

Interview Transcript (modified slightly for readability):

“Nurses play a critical role in surface disinfection processes—period. I can think back from my time when I was actually practicing as a bedside nurse, and that’s when I got into this work. One of the things that nurses have to do every single time that they get in a patient room and they leave with a piece of equipment, is they have to wipe it down; they are wiping down pieces of equipment every day, every hour, every instance at their work.

They get involved in the selection process because they have to choose something that they also like. In addition, they also have to be part of the process about how things truly work. I see nurses getting involved in the process of actually identifying that one product that they have right now that doesn’t work or acknowledging a new product that does work and continuously evaluate it.

Therefore, nurses are a very critical part of the process, and one of the things that I always say to people is that we’re all going to be patients one day and nurses get a frontline view about what’s going on in the health care system, and so, they are a key, integral part of the process of selecting disinfectants.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.